Abstract

Malaria is a devastating disease resulting in significant morbidity and mortality, especially in the developing world. Previously, we showed that the gut microbiome modulates severity of malaria in mice, though the exact mechanism was unknown. One well-studied mechanism by which the intestinal microbiota exerts an effect on host health is by synthesis of short-chain fatty acids (SCFAs). SCFAs have pleiotropic effects on the host, including modulating the immune system and altering susceptibility to pathogens. The objective of the current work was to explore if gut microbiota-mediated resistance and susceptibility to malaria in mice is through differential production of SCFAs. Of the eight detected SCFAs, only propionic acid (C3) was different between two groups of resistant and two groups of susceptible mice, with higher levels in feces of susceptible mice compared to resistant mice. Nevertheless, subsequent analysis revealed no robust correlation between malaria severity and levels of fecal propionic acid. In spite of the broad effect of SCFAs on host physiology, including host immunity, this study shows that gut microbiota-mediated modulation of malaria severity in mice is independent of fecal SCFA levels. Additionally, our data indicates that intestinal SCFAs do not function as biomarkers for prediction of malaria disease severity.

Highlights

  • Plasmodium infections remain a major health problem in tropical and sub-tropical countries, especially sub-Saharan Africa [1]

  • We have previously shown that mice from Taconic Biosciences (Tac) and Jackson Laboratory (Jax) are resistant to severe P. yoelii infection, while mice from Envigo (Env) and Charles River Laboratories (CR) were susceptible [15]

  • This current work establishes that differential production of intestinal shortchain fatty acids (SCFAs) by the gut microbiota is not a mechanism behind this phenotype

Read more

Summary

Introduction

Plasmodium infections remain a major health problem in tropical and sub-tropical countries, especially sub-Saharan Africa [1]. Therapeutic strategies to ameliorate the morbidity and mortality associated with malaria aim to reduce the severity of blood stage Plasmodium infections [2]. We reported that the host gut microbiota can modulate the severity of Plasmodium yoelii 17XNL blood stage infections in C57BL/6 mice [3]. Similar and agematched mice from different commercial sources having different gut microbiota composition were shown to display differential susceptibility to blood stage parasite density and disease severity. The resistant mice demonstrated a more robust humoral and cellular adaptive immune response in comparison to the susceptible mice. The mechanism determining resistance versus susceptibility to malaria severity has not been identified

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call